AU2003256783A1 - METHODS FOR IMPROVEMENT OF LUNG FUNCTION USING TGF-Beta INHIBITORS - Google Patents

METHODS FOR IMPROVEMENT OF LUNG FUNCTION USING TGF-Beta INHIBITORS

Info

Publication number: AU2003256783A1
Authority: AU; Australia
Prior art keywords: tgf; improvement; methods; lung function; beta inhibitors
Prior art date: 2002-07-25
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU2003256783A

Inventor

Zhihe Li

David Y. Liu

Jing Ying Ma

Andrew Protter

George F. Schreiner

Thomas-Toan Tran

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Scios LLC

Original Assignee

Scios LLC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-07-25

Filing date

2003-07-23

Publication date

2004-02-16

2003-07-23 Application filed by Scios LLC filed Critical Scios LLC

2004-02-16 Publication of AU2003256783A1 publication Critical patent/AU2003256783A1/en

Status Abandoned legal-status Critical Current

Links

102000004887 Transforming Growth Factor beta Human genes 0.000 title 1
108090001012 Transforming Growth Factor beta Proteins 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1
230000004199 lung function Effects 0.000 title 1
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

AU2003256783A 2002-07-25 2003-07-23 METHODS FOR IMPROVEMENT OF LUNG FUNCTION USING TGF-Beta INHIBITORS Abandoned AU2003256783A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US39936902P	2002-07-25	2002-07-25
US60/399,369		2002-07-25
PCT/US2003/023240 WO2004010929A2 (en)	2002-07-25	2003-07-23	METHODS FOR IMPROVEMENT OF LUNG FUNCTION USING TGF-β INHIBITORS

Publications (1)

Publication Number	Publication Date
AU2003256783A1 true AU2003256783A1 (en)	2004-02-16

Family

ID=31188573

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2003256783A Abandoned AU2003256783A1 (en)	2002-07-25	2003-07-23	METHODS FOR IMPROVEMENT OF LUNG FUNCTION USING TGF-Beta INHIBITORS

Country Status (4)

Country	Link
EP (1)	EP1575506A4 (en)
AU (1)	AU2003256783A1 (en)
CA (1)	CA2494367A1 (en)
WO (1)	WO2004010929A2 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2006524633A (en) *	2002-11-22	2006-11-02	サイオス・インコーポレーテツド	Methods for counteracting pathological changes in the β-adrenergic pathway
WO2004081009A1 (en)	2003-03-12	2004-09-23	Millennium Pharmaceuticals, Inc.	Quinazoline derivatives as tgf-beta inhibitors
JP4036885B2 (en)	2003-09-19	2008-01-23	アストラゼネカアクチボラグ	Quinazoline derivatives
EP1899332A1 (en)	2005-06-24	2008-03-19	Gilead Sciences, Inc.	Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for treating hepatitis c.
WO2007050793A2 (en) *	2005-10-25	2007-05-03	The Johns Hopkins University	Methods and compositions for the treatment of marfan syndrome and associated disorders
US8338435B2 (en)	2006-07-20	2012-12-25	Gilead Sciences, Inc.	Substituted pyrido(3,2-D) pyrimidines and pharmaceutical compositions for treating viral infections
DK2918288T3 (en)	2006-10-03	2017-11-27	Genzyme Corp	Use of TGF-beta antagonists in the treatment of infants at risk of developing bronchopulmonary dysplasia
WO2008071605A2 (en) *	2006-12-15	2008-06-19	F. Hoffmann-La Roche Ag	Methods of treating inflammatory diseases
TW200840584A (en)	2006-12-26	2008-10-16	Gilead Sciences Inc	Pyrido(3,2-d)pyrimidines useful for treating viral infections
US8536187B2 (en)	2008-07-03	2013-09-17	Gilead Sciences, Inc.	2,4,6-trisubstituted pyrido(3,2-d)pyrimidines useful for treating viral infections
EP2379076B1 (en)	2008-12-23	2014-11-12	The Trustees of Columbia University in the City of New York	Phosphodiesterase inhibitors and uses thereof
PE20130376A1 (en)	2010-06-28	2013-03-30	Merck Patent Gmbh	[1,8] NAPHTHYRIDINES SUBSTITUTED BY 2,4-DIARYLL AS KINASE INHIBITORS FOR USE AGAINST CANCER
WO2012027495A1 (en)	2010-08-27	2012-03-01	University Of The Pacific	Piperazinylpyrimidine analogues as protein kinase inhibitors
KR20140022829A (en)	2011-03-09	2014-02-25	메르크 파텐트 게엠베하	Pyrido [2, 3 - b] pyrazine derivatives and their therapeutical uses
WO2013014262A1 (en)	2011-07-27	2013-01-31	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for diagnosing and treating myhre syndrome
BR112014009789A2 (en)	2011-10-26	2017-04-25	Seattle Children's Res Inst	cysteamine in the treatment of fibrotic disease
TW201825465A (en)	2016-09-23	2018-07-16	美商基利科學股份有限公司	Phosphatidylinositol 3-kinase inhibitors
TW201815787A (en)	2016-09-23	2018-05-01	美商基利科學股份有限公司	Phosphatidylinositol 3-kinase inhibitors
TW201813963A (en)	2016-09-23	2018-04-16	美商基利科學股份有限公司	Phosphatidylinositol 3-kinase inhibitors
PT3691620T (en)	2017-10-05	2022-10-06	Fulcrum Therapeutics Inc	P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
US10342786B2 (en)	2017-10-05	2019-07-09	Fulcrum Therapeutics, Inc.	P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
CN109053597B (en) *	2018-06-14	2021-03-19	温州医科大学附属第二医院、温州医科大学附属育英儿童医院	Inflammation inhibiting compound and preparation method thereof
CN108912059B (en) *	2018-06-14	2021-03-02	温州医科大学附属第一医院	Synthetic method of nitrogenous heterocyclic inflammation inhibiting compound
CN108912060B (en) *	2018-06-14	2021-03-19	温州医科大学	Quinazoline anti-inflammatory compound and synthesis method thereof
CN108727282B (en) *	2018-06-14	2021-03-02	温州医科大学附属第一医院	Benzene sulfonyl amino-containing anti-inflammatory compound and synthesis method thereof
CN108912061B (en) *	2018-06-14	2021-03-19	温州医科大学	Synthetic method of quinazoline inflammation inhibition compound
CN108727283B (en) *	2018-06-14	2021-03-02	温州医科大学附属第一医院	Synthesis method of benzenesulfonyl amide anti-inflammatory compound
US20220177978A1 (en)	2019-04-02	2022-06-09	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods of predicting and preventing cancer in patients having premalignant lesions
CN112568188B (en) *	2021-02-24	2021-05-25	澎立生物医药技术（上海）有限公司	Method for preparing Brown Norway rat pulmonary fibrosis model
EP4323356A1 (en)	2021-04-13	2024-02-21	Nuvalent, Inc.	Amino-substituted heterocycles for treating cancers with egfr mutations

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4366189A (en) *	1979-12-21	1982-12-28	Ciba-Geigy Corporation	4-Heterocyclyl-4'-vinylstilbenes
JP2657760B2 (en) *	1992-07-15	1997-09-24	小野薬品工業株式会社	4-aminoquinazoline derivatives and pharmaceuticals containing them
US6184226B1 (en) *	1998-08-28	2001-02-06	Scios Inc.	Quinazoline derivatives as inhibitors of P-38 α
US6492497B1 (en) *	1999-04-30	2002-12-10	Cambridge Antibody Technology Limited	Specific binding members for TGFbeta1
AR029803A1 (en) *	2000-02-21	2003-07-16	Smithkline Beecham Plc	IMIDAZOLS REPLACED WITH PIRIDILE AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM
AU2001296871A1 (en) *	2000-09-15	2002-03-26	Vertex Pharmaceuticals Incorporated	Pyrazole compounds useful as protein kinase inhibitors
WO2002040468A1 (en) *	2000-11-16	2002-05-23	Smithkline Beecham Corporation	Compounds
EP1351691A4 (en) *	2000-12-12	2005-06-22	Cytovia Inc	SUBSTITUTED 2-ARYL-4-ARYLAMINOPYRIMIDINES AND THEIR ANALOGS AS ACTIVATORS OF CASPASES AND APOPTOSIS INDUCTORS, AND THEIR USE
GB0102672D0 (en) *	2001-02-02	2001-03-21	Glaxo Group Ltd	Compounds
US20040038856A1 (en) *	2002-05-17	2004-02-26	Sarvajit Chakravarty	Treatment of fibroproliferative disorders using TGF-beta inhibitors
JP2006524633A (en) *	2002-11-22	2006-11-02	サイオス・インコーポレーテツド	Methods for counteracting pathological changes in the β-adrenergic pathway

2003
- 2003-07-23 CA CA002494367A patent/CA2494367A1/en not_active Abandoned
- 2003-07-23 EP EP03771821A patent/EP1575506A4/en not_active Withdrawn
- 2003-07-23 AU AU2003256783A patent/AU2003256783A1/en not_active Abandoned
- 2003-07-23 WO PCT/US2003/023240 patent/WO2004010929A2/en not_active Ceased

Also Published As

Publication number	Publication date
WO2004010929A3 (en)	2005-12-01
WO2004010929A2 (en)	2004-02-05
EP1575506A4 (en)	2008-04-23
CA2494367A1 (en)	2004-02-05
EP1575506A2 (en)	2005-09-21

Publication	Publication Date	Title
AU2003256783A1 (en)	2004-02-16	METHODS FOR IMPROVEMENT OF LUNG FUNCTION USING TGF-Beta INHIBITORS
AU2003202263A1 (en)	2003-07-30	Roh-kinase inhibitors
AU2003261434A1 (en)	2004-02-25	Iminothiazolidinones as inhibitors of hcv replication
AU2003278088A1 (en)	2004-05-25	Heteroaryloxy-substituted phenylaminopyrimidines as rho-kinase inhibitors
AU2003255376A1 (en)	2004-03-11	Piperidine-derivatives as pde4 inhibitors
AU2003253664A1 (en)	2003-12-31	Compositions and methods for reducing lung volume
AU2003301302A1 (en)	2004-05-04	Pyradazine compounds as gsk-3 inhibitors
AU2003271566A1 (en)	2004-03-03	Pyrrolopyrazines as kinase inhibitors
AU2003217105A1 (en)	2003-09-16	Novel of cytokine inhibitors
AU2003249683A1 (en)	2003-12-22	Nf-:b inhibitors
AU2003277596A1 (en)	2004-07-29	Method of deuterization
AU2003299901A1 (en)	2004-05-04	Thrombin inhibitors
AU2003302588A1 (en)	2004-06-23	Phosphodiesterase 10a inhibitors
AU2003215635A1 (en)	2003-10-13	Thiazol-2-yl-imine compounds as pde-7 inhibitors
AU2003234925A1 (en)	2003-12-02	TGF-Alpha EXPRESSION INHIBITORS
AU2003256323A1 (en)	2004-01-19	Sos1 inhibitors
AU2003295638A1 (en)	2004-06-18	NOVEL INHIBITORS OF Beta-LACTAMASE
AUPS096002A0 (en)	2002-03-28	Method of construction
AU2003213107A1 (en)	2003-09-09	Methods for analysis of molecular events
AU2003229459A1 (en)	2003-12-02	Methods of using thiazolidinedithione derivatives
AU2003232362A1 (en)	2003-12-22	4-pyrazol-phenylalanine derivatives as ace-nep inhibitors
AU2003290512A1 (en)	2005-04-14	Method of weldbonding
AU2003299792A1 (en)	2004-09-28	Methods for the identification of inhibitors of pyrroline-5-carboxylate reductase as antibiotics
AU2003239092A1 (en)	2004-01-19	Methods for identifying novel transcription inhibitors
AU2003215235A1 (en)	2003-09-04	Cks1 INHIBITORS

Legal Events

Date	Code	Title	Description
2005-05-12	MK6	Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase